CR10798A - Terapia de combinacion en secuencia - Google Patents

Terapia de combinacion en secuencia

Info

Publication number
CR10798A
CR10798A CR10798A CR10798A CR10798A CR 10798 A CR10798 A CR 10798A CR 10798 A CR10798 A CR 10798A CR 10798 A CR10798 A CR 10798A CR 10798 A CR10798 A CR 10798A
Authority
CR
Costa Rica
Prior art keywords
combination therapy
sequence combination
angiogenesis
disorders related
administration
Prior art date
Application number
CR10798A
Other languages
English (en)
Inventor
Rakesh K Jain
Clive R Wood
Daniel T Dransfield
Antonio Arulanandam
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CR10798A publication Critical patent/CR10798A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se divulgan nuevos metodos de tratamiento de trastornos relacionados con la angiogenesis. Los trastornos relacionados con la angiogenesis se tratan por la administracion de un agente de union al ectodominio Tiel y de una gente antagonista de VEGF.
CR10798A 2006-10-17 2009-05-15 Terapia de combinacion en secuencia CR10798A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85226306P 2006-10-17 2006-10-17
US87573606P 2006-12-19 2006-12-19

Publications (1)

Publication Number Publication Date
CR10798A true CR10798A (es) 2009-06-09

Family

ID=39314809

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10798A CR10798A (es) 2006-10-17 2009-05-15 Terapia de combinacion en secuencia

Country Status (17)

Country Link
US (1) US20080160019A1 (es)
EP (1) EP2073826A4 (es)
JP (1) JP2010506951A (es)
KR (1) KR20090067214A (es)
AU (1) AU2007311092A1 (es)
BR (1) BRPI0717760A2 (es)
CA (1) CA2666714A1 (es)
CR (1) CR10798A (es)
EA (1) EA200900562A1 (es)
EC (1) ECSP099336A (es)
IL (1) IL198026A0 (es)
MA (1) MA30901B1 (es)
MX (1) MX2009004070A (es)
NI (1) NI200900057A (es)
NO (1) NO20091375L (es)
TN (1) TN2009000136A1 (es)
WO (1) WO2008048996A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528720A (ja) * 2003-08-12 2007-10-18 ダイアックス コーポレイション Ｔｉｅ１結合リガンド
WO2005107461A2 (en) * 2004-04-07 2005-11-17 The General Hospital Corporation Modulating lymphatic function
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
US20130028920A1 (en) * 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
US20150003204A1 (en) * 2013-06-27 2015-01-01 Elwha Llc Tactile feedback in a two or three dimensional airspace
US9804675B2 (en) 2013-06-27 2017-10-31 Elwha Llc Tactile feedback generated by non-linear interaction of surface acoustic waves

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4926320B2 (ja) * 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
JP2007528720A (ja) * 2003-08-12 2007-10-18 ダイアックス コーポレイション Ｔｉｅ１結合リガンド
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
WO2006020706A2 (en) * 2004-08-12 2006-02-23 Dyax Corp. Tie complex binding proteins
WO2008089070A2 (en) * 2007-01-12 2008-07-24 Dyax Corp. Combination therapy for the treatment of cancer

Also Published As

Publication number Publication date
EP2073826A4 (en) 2010-12-15
US20080160019A1 (en) 2008-07-03
MA30901B1 (fr) 2009-11-02
AU2007311092A1 (en) 2008-04-24
MX2009004070A (es) 2009-04-27
IL198026A0 (en) 2011-08-01
WO2008048996A2 (en) 2008-04-24
BRPI0717760A2 (pt) 2013-11-12
JP2010506951A (ja) 2010-03-04
KR20090067214A (ko) 2009-06-24
TN2009000136A1 (en) 2010-10-18
WO2008048996A3 (en) 2008-07-03
EP2073826A2 (en) 2009-07-01
EA200900562A1 (ru) 2009-10-30
WO2008048996A9 (en) 2008-09-12
NO20091375L (no) 2009-07-10
CA2666714A1 (en) 2008-04-24
NI200900057A (es) 2010-02-02
ECSP099336A (es) 2009-06-30

Similar Documents

Publication Publication Date Title
CR10798A (es) Terapia de combinacion en secuencia
NO20054371L (no) Somatostatin-dopamin kimaere analoger
HK1139930A1 (en) Cyclopamine lactam analogs and methods of use thereof
MX2009009428A (es) Analogos de ciclopamina heterociclicos y metodos de uso de los mismos.
MA32161B1 (fr) Formes de rifaximine et utilisations de celles-ci
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
RS54156B1 (en) COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA201170592A1 (ru) Комбинированная терапия с применением пептид эпоксикетонов
DK2167117T3 (da) Anvendelse af VWF-stabiliserede FVIII-præparater til ekstravaskulær administration til terapeutisk og profylaktisk behandling af blødningsforstyrrelser
UA109658C2 (xx) Антитіло проти cgrp
RS52102B (en) PIRPHENIDONE THERAPY Avoiding FLUVOXAMINE
NZ584042A (en) Use of mva to treat prostate cancer
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201070609A1 (ru) Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств
CY1114023T1 (el) Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog
CR8850A (es) Composicion y metodo para tratar hemorroides y/o transtornos ano-rectales
CR10997A (es) Metodo de tratamiento de canceres
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
WO2007033140A3 (en) Prok2 antagonists and methods of use
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н
EA200970816A1 (ru) Новая лекарственная форма
CL2007000554A1 (es) Metodo para diagnosticar matastasis en el nodulo linfatico de un carcinoma gastrico; y metodo para determinar o ajustar una terapia para un paciente con carcinoma gastrico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)